Oncology

AbbVie CEO Is on Deck as Antitrust Hearings Heat Up

May 3rd 2021

By Tony Hagen

Representative Carolyn B. Maloney, D-New York, questions the use of pharmaceutical profits to defend against biosimilar competition.

Reports From Biocon, Celltrion on Finances, COVID-19 Treatments

May 1st 2021

By Tony Hagen

Biocon tests the waters with itolizumab in pandemic-ravaged India, and Celltrion announces early success with an agent for the South African variant.

Amgen, Merck, Teva Provide First-Quarter Biosimilars Info

April 30th 2021

By Tony Hagen

There's no end in sight for Enbrel (etanercept) sales erosion, but Amgen's biosimilars are holding their own, the company reported.

Toothful or Toothless? Biden's Biosimilar Bills Under the Microscope

April 28th 2021

By Tony Hagen

How much muscle did Congress invest in a pair of bills recently signed by President Biden? The answer may lie in your willingness to believe.

Investigators Measure Pegfilgrastim Biosimilar Savings Potential

April 27th 2021

By Deana Ferreri, PhD

The savings from pegfilgrastim biosimilars rapidly add up, according to a study simulation that accounted for hospital costs associated with the on-body injector.

Kaiser Permanente Study Demonstrates Equivalence for Mvasi

April 26th 2021

By Tony Hagen

Investigators tapped health system data to conduct an observational, real-world comparison of bevacizumab (Mvasi) vs the reference product (Avastin).

Not So Different: What’s Stopping Physicians From Prescribing Biosimilars?

April 25th 2021

This is the second of a 3-part series on National Comprehensive Cancer Network/Pfizer efforts to investigate issues of importance to biosimilar stakeholders.

Samsung Bioepis Racks Up More Awards for Its Biosimilar Packaging

April 24th 2021

By Tony Hagen

Medicinal packaging shouldn't remind patients that they have a condition, according to Samsung Bioepis.

Medicines for Europe Panel Tackles Biosimilar Uptake

April 23rd 2021

By Tony Hagen

The European Union is a diverse market with pockets of biosimilar resistance but also cost-saving triumphs, panelists said at the Biosimilar Medicines Virtual Summit 2021.

Roche Sees Rejuvenation Amid Sales Declines From Biosimilars, COVID-19

April 21st 2021

By Tony Hagen

Roche has begun another year of biosimilar sales erosion, although the company has said this year will not be as bad as 2020.